These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 6401351)

  • 1. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients.
    Judzewitsch RG; Jaspan JB; Polonsky KS; Weinberg CR; Halter JB; Halar E; Pfeifer MA; Vukadinovic C; Bernstein L; Schneider M; Liang KY; Gabbay KH; Rubenstein AH; Porte D
    N Engl J Med; 1983 Jan; 308(3):119-25. PubMed ID: 6401351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of glycemic control and aldose reductase inhibition on nerve conduction velocity.
    Pfeifer MA
    Am J Med; 1985 Nov; 79(5A):18-23. PubMed ID: 3934964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials of sorbinil on nerve function.
    Pfeifer MA
    Metabolism; 1986 Apr; 35(4 Suppl 1):78-82. PubMed ID: 3083211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes.
    Jaspan JB; Towle VL; Maselli R; Herold K
    Metabolism; 1986 Apr; 35(4 Suppl 1):83-92. PubMed ID: 3083212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy.
    Lewin IG; O'Brien IA; Morgan MH; Corrall RJ
    Diabetologia; 1984 Jun; 26(6):445-8. PubMed ID: 6432615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy.
    Jaspan JB; Herold K; Bartkus C
    Am J Med; 1985 Nov; 79(5A):24-37. PubMed ID: 3000176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats.
    Yue DK; Hanwell MA; Satchell PM; Turtle JR
    Diabetes; 1982 Sep; 31(9):789-94. PubMed ID: 6819173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil.
    O'Hare JP; Morgan MH; Alden P; Chissel S; O'Brien IA; Corrall RJ
    Diabet Med; 1988 Sep; 5(6):537-42. PubMed ID: 2974776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diabetic neuropathy: treatment trial with an aldose reductase inhibitor (Sorbinil)].
    Christensen JE; Larsen AB; Gregersen G
    Ugeskr Laeger; 1987 Nov; 149(46):3111-4. PubMed ID: 3127975
    [No Abstract]   [Full Text] [Related]  

  • 10. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil.
    Sima AA; Bril V; Nathaniel V; McEwen TA; Brown MB; Lattimer SA; Greene DA
    N Engl J Med; 1988 Sep; 319(9):548-55. PubMed ID: 3136331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological inhibition of aldose reductase in human diabetic neuropathy.
    Jaspan J
    Drugs; 1986; 32 Suppl 2():23-9. PubMed ID: 2431859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs.
    Engerman RL; Kern TS; Larson ME
    Diabetologia; 1994 Feb; 37(2):141-4. PubMed ID: 8163047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity.
    Sima AA; Prashar A; Nathaniel V; Bril V; Werb MR; Greene DA
    Diabet Med; 1993 Mar; 10(2):115-21. PubMed ID: 8458187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of sorbinil on peripheral nerve conduction velocity, polyol concentrations and morphology in the streptozotocin-diabetic rat.
    Cameron NE; Leonard MB; Ross IS; Whiting PH
    Diabetologia; 1986 Mar; 29(3):168-74. PubMed ID: 3084324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a new aldose reductase inhibitor, 8'-chloro-2',3'-dihydrospiro [pyrrolidine-3,6'(5'H)-pyrrolo[1,2,3-de] [1,4]benzoxazine]-2,5,5'- trione (ADN-138), on delayed motor nerve conduction velocity in streptozotocin-diabetic rats.
    Hirata Y; Fujimori S; Okada K
    Metabolism; 1988 Feb; 37(2):159-63. PubMed ID: 2828821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can aldose reductase inhibition ameliorate diabetic neuropathy?
    González ER
    JAMA; 1981 Sep; 246(11):1169-70. PubMed ID: 6790734
    [No Abstract]   [Full Text] [Related]  

  • 17. Improvement in peripheral nerve function after one year of Sorbinil.
    Gieron MA; Malone JI; Lowitt S; Korthals JK
    Neuroreport; 1991 Jun; 2(6):348-50. PubMed ID: 1655107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition.
    Gillon KR; Hawthorne JN; Tomlinson DR
    Diabetologia; 1983 Oct; 25(4):365-71. PubMed ID: 6416913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The sorbinil retinopathy trial: neuropathy results. Sorbinil Retinopathy Trial Research Group.
    Neurology; 1993 Jun; 43(6):1141-9. PubMed ID: 8170559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six-month treatment with sorbinil in asymptomatic diabetic neuropathy. Failure to improve abnormal nerve function.
    Martyn CN; Reid W; Young RJ; Ewing DJ; Clarke BF
    Diabetes; 1987 Sep; 36(9):987-90. PubMed ID: 3111914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.